Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanksApr 19 06:30 ET
Alkermes Analyst Ratings
BenzingaApr 19 06:15 ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanksApr 18 01:10 ET
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanksApr 12 01:41 ET
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
TipRanksApr 12 01:38 ET
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanksApr 10 07:20 ET
Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks
TipRanksApr 10 06:26 ET
Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential
TipRanksApr 9 20:55 ET
Alkermes's ALKS-2680 Shows Promising Efficacy in NT2, Enhancing Market Outlook and Supporting a Buy Rating
TipRanksApr 9 12:15 ET
Alkermes Analyst Ratings
BenzingaApr 9 12:06 ET
Analysts Conflicted on These Healthcare Names: Chemed (CHE) and Alkermes (ALKS)
TipRanksApr 9 11:50 ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), LifeMD (LFMD) and Apyx Medical (APYX)
TipRanksApr 9 09:10 ET
Alkermes Analyst Ratings
BenzingaApr 1 10:27 ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Opko Health (OPK) and Leafly Holdings, Inc. (LFLY)
TipRanksApr 1 07:10 ET
Baird Initiates Alkermes With Outperform Rating, Price Target Is $37
MT NewswiresMar 19 08:59 ET
Alkermes Analyst Ratings
BenzingaMar 19 04:49 ET
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
TipRanksFeb 26 07:10 ET
Alkermes Downgraded at UBS as Stock Nears 52-week High
Seeking AlphaFeb 20 12:32 ET
UBS Cuts Alkermes Rating to Sell Amid Concerns Over Pipeline Spread
InvestingFeb 20 07:16 ET
Alkermes Analyst Ratings
BenzingaFeb 20 07:09 ET
No Data
No Data